Provided by Tiger Trade Technology Pte. Ltd.

MSA Safety

181.23
+2.201.23%
Post-market: 181.230.00000.00%19:30 EDT
Volume:229.55K
Turnover:41.72M
Market Cap:6.99B
PE:22.54
High:182.98
Open:181.44
Low:181.12
Close:179.03
52wk High:208.92
52wk Low:151.11
Shares:38.58M
Float Shares:36.18M
Volume Ratio:1.09
T/O Rate:0.63%
Dividend:2.13
Dividend Rate:1.18%
EPS(TTM):8.04
EPS(LYR):7.09
ROE:23.66%
ROA:11.07%
PB:5.00
PE(LYR):25.56

Loading ...

MSA Safety raises quarterly dividend to $0.54 per share

Reuters
·
May 04

MSA Safety Inc - Raises Qtrly Dividend to $0.54 per Common Share

THOMSON REUTERS
·
May 04

MSA Safety Announces 56 Consecutive Years of Annual Dividend Increases

THOMSON REUTERS
·
May 04

Alterity Therapeutics Releases Appendix 4C – Q3 FY26 Quarterly Cash Flow Report & Corporate Update

GlobeNewswire
·
Apr 30

Press Release: OBOOK Holdings Inc. Announces Financial Results for the Full Year 2025 Ended December 31, 2025

Dow Jones
·
Apr 30

Earning Preview: MSA Safety this quarter’s revenue is expected to increase by 12.09%, and institutional views are bullish

Earnings Agent
·
Apr 27

Plus Therapeutics Initiates Manufacturing Activities with SpectronRx Under a Master Services Agreement to Support GMP Pivotal Trial Readiness for REYOBIQ™

GlobeNewswire
·
Apr 23

Alterity Therapeutics Presents New Analysis of ATH434 Phase 2 Trial Data in Late Breaking Science Session of the American Academy of Neurology

GlobeNewswire
·
Apr 22

Alterity’s ATH434 Shows Phase 2 Efficacy Signal in MSA on New Composite Scale

TIPRANKS
·
Apr 22

MSA Safety showcases G1 XR SCBA at FDIC International

Reuters
·
Apr 21

MSA Safety schedules first-quarter earnings conference call

Reuters
·
Apr 21

Press Release: Mineros S.A. Updates Market on Special Meeting of Shareholders Scheduled for April 30, 2026, and Confirms Successful Closing of Previously Announced Transaction

Dow Jones
·
Apr 17

Alterity to Spotlight ATH434 MSA Data in Late-Breaker at AAN Meeting

TIPRANKS
·
Apr 16

Alterity Therapeutics to Host Virtual KOL Event to Share New Insights on ATH434 for the Treatment of Multiple System Atrophy

GlobeNewswire
·
Apr 15

Alterity Therapeutics Showcases ATH434 Progress in Virtual MSA KOL Event

TIPRANKS
·
Apr 15

SST001, an α-syn PET tracer from Mabwell's incubated company SynuSight Biotech, received NMPA approval to initiate a clinical trial

prnewswire
·
Apr 15

Tiziana Life Sciences Announces Late Breaking Poster Accepted for Presentation at the 7th World Parkinson Congress

GlobeNewswire
·
Apr 14